5H-Pyrrolo[3,2-d]pyrimidine-4-carboxamide, 2-(1H-imidazol-1-yl)-N-[trans-4-(2-methoxyethoxy)cyclohexyl]-

Product Name: 5H-Pyrrolo[3,2-d]pyrimidine-4-carboxamide, 2-(1H-imidazol-1-yl)-N-[trans-4-(2-methoxyethoxy)cyclohexyl]-
CAS No.: 2597933-17-8
Chemical Name: 5H-Pyrrolo[3,2-d]pyrimidine-4-carboxamide, 2-(1H-imidazol-1-yl)-N-[trans-4-(2-methoxyethoxy)cyclohexyl]-
Synonyms: RBN013208;RBM013209;RBN013209, 10 mM in DMSO;2-(1-Imidazolyl)-N-[trans-4-(2-methoxyethoxy)cyclohexyl]-5H-pyrrolo[3,2-d]pyrimidine-4-carboxamide;2-(1H-imidazol-1-yl)-N-(trans-4-(2-methoxyethoxy)cyclohexyl)-5H-pyrrolo[3,2-d]pyrimidine-4-carboxamide;2-(1H-imidazol-1-yl)-N-((1r,4r)-4-(2-methoxyethoxy)cyclohexyl)-5H-pyrrolo[3,2-d]pyrimidine-4-carboxamide;5H-Pyrrolo[3,2-d]pyrimidine-4-carboxamide, 2-(1H-imidazol-1-yl)-N-[trans-4-(2-methoxyethoxy)cyclohexyl]-
CBNumber: CB910720104
Molecular Formula: C19H24N6O3
Formula Weight: 384.43
MOL File: 2597933-17-8.mol

More

Less

5H-Pyrrolo[3,2-d]pyrimidine-4-carboxamide, 2-(1H-imidazol-1-yl)-N-[trans-4-(2-methoxyethoxy)cyclohexyl]- Property

Density: 1.43±0.1 g/cm3(Predicted)
storage temp.: Store at -20°C
solubility: DMSO : 250 mg/mL (650.31 mM; Need ultrasonic)
form: Solid
pka: 11.41±0.40(Predicted)
color: Off-white to light yellow

More

Less

Hazard and Precautionary Statements (GHS)

More

Less

5H-Pyrrolo[3,2-d]pyrimidine-4-carboxamide, 2-(1H-imidazol-1-yl)-N-[trans-4-(2-methoxyethoxy)cyclohexyl]- Chemical Properties,Usage,Production

Uses

RBN013209 is an orally active small molecule inhibitor of CD38 with an IC50 of 0.01 to 0.1 μM for human CD38. RBN013209 prevents the conversion of extracellular NAD+ to ADPR or cADPR in tumor cells and PBMCs. RBN013209 can be used in the study of tumor. In addition, RBN013209 enables CAR-T cells to maintain the naive state and central memory state, and decreases the expression of cell activation markers and exhaustion-related inhibitory receptors[1][2][3].

Biological Activity

RBN013209 is a potent CD38 inhibitor and is useful in the treatment of cancer.

in vivo

RBN013209 (Oral administration) has antitumor activity in mice^[3].

Animal Model:	Mice^[3]
Dosage:	/
Administration:	Oral administration
Result:	Resulted in dose-dependent elevation of NAD⁺ and reduction of ADPR in various tissues such as spleen and liver in na?ve mice. Had antitumor activity that was associated with changes in NAD⁺ and ADPR in MC38 tumor model. Had antitumor activity in combinationwith anti-PD-L1 therapy in B16-F10 tumor-bearing mice.

References

[1]. Laurie B. Schenkel, et al. Heterobicyclic amides as inhibitors of cd38. WO2021021986 A1.

5H-Pyrrolo[3,2-d]pyrimidine-4-carboxamide, 2-(1H-imidazol-1-yl)-N-[trans-4-(2-methoxyethoxy)cyclohexyl]- Preparation Products And Raw materials

Raw materials

Preparation Products

More

Less

5H-Pyrrolo[3,2-d]pyrimidine-4-carboxamide, 2-(1H-imidazol-1-yl)-N-[trans-4-(2-methoxyethoxy)cyclohexyl]- Suppliers

China 31 United States 1 Global 32

TargetMol Chemicals Inc.

Tel: +1-781-999-5354; +17819995354
Email: marketing@targetmol.com
Country: United States
ProdList: 32435
Advantage: 58

2597933-17-8, 5H-Pyrrolo[3,2-d]pyrimidine-4-carboxamide, 2-(1H-imidazol-1-yl)-N-[trans-4-(2-methoxyethoxy)cyclohexyl]-Related Search:

5H-Pyrrolo[3,2-d]pyrimidine-4-carboxamide, 2-(1H-imidazol-1-yl)-N-[trans-4-(2-methoxyethoxy)cyclohexyl]-

RBM013209

2-(1-Imidazolyl)-N-[trans-4-(2-methoxyethoxy)cyclohexyl]-5H-pyrrolo[3,2-d]pyrimidine-4-carboxamide

2-(1H-imidazol-1-yl)-N-(trans-4-(2-methoxyethoxy)cyclohexyl)-5H-pyrrolo[3,2-d]pyrimidine-4-carboxamide

RBN013209, 10 mM in DMSO

2-(1H-imidazol-1-yl)-N-((1r,4r)-4-(2-methoxyethoxy)cyclohexyl)-5H-pyrrolo[3,2-d]pyrimidine-4-carboxamide

RBN013208

2597933-17-8